Ribon hires CMO as lead PARP drug nears clinical trials

Ribon Therapeutics has named Sudha Parasuraman as its CMO. Parasuraman, last seen occupying the same role at X4 Pharmaceuticals, joins Ribon as it works to use money from the VC groups at Johnson & Johnson and Novartis to take small molecule monoPARP inhibitors into the clinic.